Comparative studies of conjugated capsular polysaccharide of Neisseria meningitidis serogroup A with outer membrane vesicle of Neisseria meningitidis serogroup B

Research Journal of Microbiology

Volumn 2, Issue 4, 2007, Pages 337-345

  Siadat, S D ^a   Norouzian, Dariush ^a   Tabaraie, B ^a   Ahmadi, H ^a   Behzadiyannejad, Q ^b   Pirayeeh, S N ^b   Nejati, M ^a   Motlagh, B A ^c  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

Author keywords

Neisseria meningitidis serogroup A and B; Outer membrane vesicle; Polysaccharide protein conjugated vaccine

Indexed keywords

NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS SEROGROUP A; NEISSERIA MENINGITIDIS SEROGROUP B; OAT MOSAIC VIRUS; ORYCTOLAGUS CUNICULUS;

EID: 34250780621     PISSN: 18164978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Ada, G., 2001. Vaccine and vaccination. N. Eng. J. Med., 345: 1042-1053.
2. Ada, G. and D. Isaacs, 2003. Carbohydrate-protein conjugate vaccine. Clin Microbiol. Infect., 9: 79-85.
3. Anderson, E.L., T. Bowers, C.M. Mink, D.J. Kendy, R.B. Belshe, H. Harakeh, L. Pais, P. Holder and G.M. Carlone, 1994. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect. Immunol., 62: 3391-3395.
4. Arigita, C., W. Jiskoot, J. Westdijk, C. Ingen, W.E. Hennink, J.A. Daan, D.J.A. Crommelin and G.F.A. Kersten, 2004. Stability of mono-and trivalent meningococcal outer membrane vesicle vaccines. Vaccine, 22: 629-642.
5. Berry, D.C., A. Van Den Kaaden, C.E. Frasch and A.B. Leussink, 2002. Effect of acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune response. Infect. Immunol., 70: 3707-3713.
6. Bethell, D. and A.J. Pollard, 2002. Meningococcal vaccines. Exp. Rev. Vaccines, 1: 75-83.
7. Cartwright, K., R. Morris, H. Rümke, A. Fox, R. Borrow, N. Begg, P. Richmond and J. Poolman, 1999. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane protein. Vaccine, 17: 2612-2619.
8. Cartwright, K., 2001. Meningococcal disease in Europe: Epidemiology, mortality and prevention with conjugate vaccines. Report of a European advisory board meeting vienna, Austria, 6-8 October, 2000. Vaccine, 19: 4347-4356.
9. Claassen, I., J. Meylis, P. Ley, C. Peeters, H. Brons, J. Robert, D. Borsboom, A. Ark, I. Straaten, P. Roholl, B. Kuipers and J. Poolman, 1996. Production, characterization and control of Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicles vaccine. Vaccine, 14: 1001-1008.
10. Costantino, P., F. Norelli, A. Giannozzi, S.D. Ascenzi, A. Bartoloni, S. Kaur, D. Tang, R. Seid, S. Viti, R. Paffetti, M. Bigio, C. Pennatini, G. Averani, V. Guarnieri, E. Gallo, N. Ravenscroft, C. Lazzeroni, R. Rappuoli and C. Ceccarini, 1999. Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines. Vaccine, 17: 1251-1263.
11. Fukasawa, L.O., M.C. Gorla, R.P. Schekman, L.R. Garcia, S.M. Carneiro, I. Raw and M.M. Tanizaki, 1999. Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate. Vaccine, 17: 2951-2958.
12. Fukasawa, LO., W.O. Dias, R.P.F. Schenkman, I. Raw and M.M. Tanizaki, 2004. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroup B/C in neonatal mice. FEMS. Immunol. Med. Microbiol., 41: 205-210.
13. Gudlavalleti, S.K., A.K. Datta, Y.L. Tzeng, C. Noble, R.W. Carlson and D.S. Stephens, 2004. The Neisseria meningitidis serogroup A capsular polysaccharide O-3 and O-4 acetyltransferase. J. Biol. Chem., 279: 42765-42773.
14. Gupta, R.K., W. Egan, D.A. Bryla, J.B. Robbins and S. Szu, 1995. Comparative immunogenicity of conjugates composed of Escherichia coli 0111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazin, bound to tetanus toxoid by two synthetic schemes. Infect. Immunol., 63: 2805-2810.
15. Hestrin, S., 1949. The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamin and it's analytical application. J. Biol. Chem., 180: 249-261.
16. Hossany, R.B., M.A. Johanson, A.A. Eniade and B.M. Pinto, 2004. Synthesis and immunochemical characterization of protein conjugates of carbohydrate and carbohydrate-mimic peptides as experimental vaccines. Bioorg. Med. Chem ., 12: 3743-3754.
17. Jennings, H.J. and C. Lugowski, 1981. Immunochemistry of groups A, B and C meningococcal polysaccharide tetanus toxoid conjugates. J. Immunol., 27: 1011-1018.
18. Jensen, C., B. Kuipers, J. Van Der Bienzen, H. Cock, P. Van Der Ley and J. Tommassen, 2000. Immunogenicity of in vitro folded outer membrane protein PorA of Neisseria meningitidis. FEMS Immuno. Med. Microbiol., 27: 227-233.
19. Jin, Z., C. Chu, J.B. Robbins and R. Schneerson, 2003. Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice. Infect. Immunol., 71: 5115-5120.
20. Lesinski, G.B. and M.A. Westerlink, 2001. Novel vaccine strategies to T-independent antigens. J. Microbiol. Meth., 47: 135-149.
21. Lindberg, A.A., 1999. Glycoprotein conjugate vaccines. Vaccine, 17: 28-36.
22. Liu, T.Y., E.C. Gotschlich, E.K. Jonssen and J.R. Wysocki, 1971. Studies on the meningococcal polysaccharides. J. Biol. Chem., 246: 2849-2858.
23. Milagres, L.G., M.C.A. Gorla, C.T. Sacchi, 1998. Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with a outer membrane vaccine. Infect. Immunol., 66: 4755-4761.
24. Mond, J.J., A. Lees, C.M. Snapper, 1995. T-cell independent antigens type 2. Ann. Rev. Immunol., 13: 655-692.
25. Norheim, G., A. Aase, D.A. Caugant, E.A. Hoiby, E. Fritzsonn, T. Tangen, P. Kristiansen, U. Heggelund and E. Rosenqvist, 2005. Development and characterization of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. Vaccine, 23: 3762-3774.
26. Ouctherlony, O., 1962. Diffusion in gel methods for immunological analysis. Allergy, 6: 30-39.
27. Paviakova, D., C. Chu, S. Bystrichy, N.W. Tolson, J. Schiloach, J.B. Kaufman, D.A. Bryla, J.B. Robbins and R. Schneeson, 1999. Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice. Infect. Immunol., 67: 5526-5529.
28. Peeters, C.C.A.M., H.C. Rumke, L.C. Sudermann, E.M.R. Voort, J. Meulenbelt, M. Schuller, A.J. Kuipers, P. Ley and J.T. Poolman, 1996. Phase I clinical trial with a hexavalent Por A containing meningococcal outer membrane vesicle vaccine. Vaccine, 14: 1009-1015.
29. Peeters, C., I. Claassen, M. Schuller, G.F.A. Kersten, Van Der Voort and J.T. Poolman, 1999. Immunogenicity of various presentation forms of Por A outer membrane protein of Neisseria meningitidis in mice. Vaccine, 17: 2702-2712.
30. Perez-Melgosa, M., H.D. Ochs, P.S. Linsley, 2001. Carrier-mediated enhancement of cognate T cell help: The basis for enhanced immunogenicity of meningoccocal outer membrane protein polysaccharide conjugate vaccine. Eur. J. Immunol., 31: 2373-2381.
31. Peterson, G.L., 1977. A simpilification of the protein assay of Lowry et al. Which is more generally applicable. Anal. Biochem., 83: 346-356.
32. Pyrogen test, In: United states pharmacopoeia 23 rd 1995. Revision, US, pharmacopoeial convention Inc., Rockville, M.D., D. 1718.
33. Ravenscraft, N., G. Averani and A. Bartoloni, 1999. Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines. Vaccine, 17: 2802-2816.
34. Rosenstin, N.E., B.A. Perkins, D.S. Stephens, T. Popovic and J.M. Hughes, 2001. Meningococcal disease. N. Engl. J. Med., 344: 1378-1388.
35. Ruggeberg, J.U. and A.J. Pollard, 2004. Meningococcal vaccines. Pediat Drugs, 6: 251-266.
36. Schmidt, S., D. Zhu, V. Barniak, K. Mason, Y. Zahang, R. Arumugham and T. Metcalf, 2001. Passive immunization with Neisseria meningitidis PorA specific immune sera reduces nasopharyngeal colonization of group B meningococcus in an infant rat nasal challenge model. Vaccine, 19: 4851-4858.
37. Schneerson, R., O. Barrera, A. Sutton and J.B. Robbins, 1980. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide protein conjugates. J. Exp. Med., 152: 361-376.
38. Vella, P.P., J.M. Staub, J. Armstrong, K.T. Dolan, C.R. Rusk, S. Szymanski, W.E. Greer, S. Murburg, P.J. Keniskern, M.A. Schofield, R.L. Tolman, F. Hartner, S. Pan, R.J. Gerety and W. Ellis, 1990. Immunogenicity a new Haemophilus influenzae type b conjugate vaccine (Meningococcal protein conjugate) (Pedvax HIB). Pediatrics, Supplement, pp: 668-675.
39. World Health Organization, 1976. Requirements for meningococcal polysaccharide vaccine. World Health Organ. Tech. Rep. Ser., 594: 50-75.